{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:19:32Z","timestamp":1789697972793,"version":"4.0.1"},"reference-count":15,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Precocious puberty (PP) in girls with McCune-Albright syndrome (MAS) is characterized by episodic development of large unilateral ovarian cysts followed by sudden onset of vaginal bleeding. Some patients experience frequent bleeding as well as accelerated linear growth and advanced skeletal maturation. The use of anastrozole for the treatment of PP in this condition has not been well studied.<\/jats:p>\n               <jats:p>Objective: The objective of the study was to determine the safety and efficacy of the aromatase inhibitor anastrozole for the treatment of PP in girls with MAS.<\/jats:p>\n               <jats:p>Design and Settings: This was a prospective international multicenter study in which subjects received anastrozole 1 mg daily for 1 yr.<\/jats:p>\n               <jats:p>Patients: Twenty-eight girls 10 years of age or younger with MAS and progressive PP were enrolled.<\/jats:p>\n               <jats:p>Main Outcome Measures: Vaginal bleeding, rate of skeletal maturation (change in bone age over change in chronological age), growth velocity, and uterine\/ovarian volumes were measured. These indices were compared with a 6-month pretreatment interval.<\/jats:p>\n               <jats:p>Results: No difference in vaginal bleeding (mean number of days per year) was noted. Mean change in \u0394BA\/\u0394CA, which was 1.25 \u00b1 0.77 at baseline, was \u22120.25 \u00b1 1.02 at study end (P = 0.22). Average growth velocity z score was 1.40 \u00b1 3.15 at study entry and 0.26 \u00b1 2.71 at 12 months (P = 0.10). Mean ovarian\/uterine volumes were unaffected by anastrozole, and no significant adverse events occurred.<\/jats:p>\n               <jats:p>Conclusions: Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Pharmacological strategies other than anastrozole should be pursued for the treatment of PP in this population.<\/jats:p>","DOI":"10.1210\/jc.2007-2090","type":"journal-article","created":{"date-parts":[[2008,4,9]],"date-time":"2008-04-09T00:54:04Z","timestamp":1207702444000},"page":"2751-2754","source":"Crossref","is-referenced-by-count":49,"title":["The Aromatase Inhibitor Anastrozole Is Ineffective in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome"],"prefix":"10.1210","volume":"93","author":[{"given":"Jakub","family":"Mieszczak","sequence":"first","affiliation":[{"name":"Department of Pediatrics (J.M., E.A.E.), Section of Pediatric Endocrinology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of AstraZeneca (E.S.L.), Wilmington, Delaware 19850"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Plourde","sequence":"additional","affiliation":[{"name":"Department of EUSA Pharma (P.P.), Doylestown, Pennsylvania 18901"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Eugster","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (J.M., E.A.E.), Section of Pediatric Endocrinology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613464816200_R1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJM193704292161701","article-title":"Syndrome characterized by osteitis fibrosa disseminate, areas of pigmentation and endocrine dysfunction, with precocious puberty in females.","volume":"216","author":"Albright","year":"1937","journal-title":"N Engl J Med"},{"key":"2020071613464816200_R2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med"},{"key":"2020071613464816200_R3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00019616-199309000-00008","article-title":"Endocrine manifestations of McCune-Albright syndrome.","volume":"3","author":"Foster","year":"1993","journal-title":"Endocrinologist"},{"key":"2020071613464816200_R4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1203\/00006450-198609000-00010","article-title":"Ovarian function in girls with McCune-Albright syndrome.","volume":"20","author":"Foster","year":"1986","journal-title":"Pediatr Res"},{"key":"2020071613464816200_R5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00024677-200403030-00002","article-title":"Aromatase inhibitors in precocious puberty: rationale and experience to date.","volume":"3","author":"Eugster","year":"2004","journal-title":"Treat Endocrinol"},{"issue":"Suppl 3","key":"2020071613464816200_R6","first-page":"945","article-title":"Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome","volume":"15","author":"Roth","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071613464816200_R7","first-page":"293","volume-title":"Program of the 85th Annual Meeting of The Endocrine Society","author":"Kunz","year":"2003"},{"key":"2020071613464816200_R8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1651-2227.1998.tb00921.x","article-title":"Pelvic ultrasonography in normal girls and in girls with pubertal precocity.","volume":"87","author":"Buzi","year":"1998","journal-title":"Acta Paediatr"},{"key":"2020071613464816200_R9","first-page":"647","article-title":"Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.","volume":"77","author":"Feuillan","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613464816200_R10","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1210\/jc.2003-030864","article-title":"Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.","volume":"88","author":"Nunez","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613464816200_R11","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1210\/jc.2007-0247","article-title":"Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.","volume":"92","author":"Azim","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613464816200_R12","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1210\/jc.2006-2350","article-title":"Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.","volume":"92","author":"Feuillan","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613464816200_R13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-3476(03)00128-8","article-title":"Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial.","volume":"143","author":"Eugster","year":"2003","journal-title":"J Pediatr"},{"key":"2020071613464816200_R14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1515\/JPEM.2004.17.12.1597","article-title":"An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys.","volume":"17","author":"Mauras","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071613464816200_R15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jsbmb.2006.09.003","article-title":"Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.","volume":"102","author":"Ariazi","year":"2006","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/7\/2751\/9059151\/jcem2751.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/7\/2751\/9059151\/jcem2751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:37:37Z","timestamp":1594946257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/7\/2751\/2598990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-2090","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}